Enasidenib
IDH2 Gene Mutation
University Health Network, TorontoSmall moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the IDH2 Gene Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Busulphan University of Utah | Phase 2 | CCC |
Cyclophosphamide University of Utah | Phase 2 | CCC |
Romidepsin University of Utah | Phase 2 | CCC |
Azacitidine M.D. Anderson Cancer Center | Phase 2 | CCC |
Fludarabine University of Utah | Phase 2 | CCC |
Venetoclax University Health Network, Toronto | Phase 1/2 | CCC |
Pamiparib University of California, San Francisco | Phase 1 | CC |
Same molecule, other indications
Enasidenib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →